SPHN report 2016-2019

SPHN (Swiss Personalized Health Network) has just issued its first report describing the advancement of all currently funded projects.

Next Generation Sequencing Platform, University of Bern: Virtual PacBio Day on February 23, 2021

This 3-hour event provides you with the opportunity to hear from your peers about their latest discoveries and how Single Molecule, Real-Time (SMRT) Sequencing can help answer your toughest biological questions.
The Sequel System, available at the Next Generation Sequencing Platform at the University of Bern, delivers a comprehensive view of genomes, transcriptomes and epigenomes.
Registration is now open

SRF radio podcast: Covid-19 and its effect on lung function

Dr. Manuela Funke-Chambour, Department for Pulmonary Medicine, Inselspital, is interviewed on Swiss national radio SRF (in german) on how Covid-19 affects the lung of patients, particularly long-term.

Confederation supports 2nd SPHN funding period 2021-2024 totalling CHF 66.9 Mio

The Confederation renews the mandate of the Swiss Academies of Medical Sciences (SAMS) and the SIB Swiss Institute of Bioinformatics for a second SPHN funding period for 2021 to 2024.

***UPDATE***: Swiss Stem Cell Network (SCCN) 15th Annual Meeting 2020: Dec 11, 2020: eMeeting via Zoom

Co-hosted by the platform for Stem Cell Research in Regenerative Medicine (SCRM) and the Bern Center for Precision Medicine (BCPM): "Innovation in Clinical Bio-manufacturing". General topic: Organoids & other specialized cell cultures for clinical applications.
Click for more information and the final program.

New discovery in Prostate Cancer research

Dr. Anke Augspach and Prof. Mark Rubin led an international team that has identified a novel vulnerability in advanced prostate cancer that is no longer responding to hormonal therapy. These findings could lead to the development of new treatment approaches for men suffering from the most aggressive form of prostate cancer.

New BCPM Executive Board elected

The BCPM members have elected a new Executive Board. We are happy to present the seven board members, and we wish to express our appreciation to the departing board members Prof. Dr. Claudia Kühni and Prof. Dr. Tosso Leeb for their valuable contribution during the last years.

ERA-NET PerMed: Joint transnational call for proposals (2021)

PRE-ANNOUNCEMENT:
Joint transnational call for proposals (2021) for “Multidisciplinary Research Projects on Personalised Medicine - Development of Clinical Support Tools for Personalised Medicine Implementation".
Call opens December 14, 2020
Submission deadline for pre-proposals: March 4th 2021

3RCC project award for "Development of a platform for GU cancer patient-derived organoids"

Congratulations to BCPM members Dr Marianna Kruithof-de-Julio and Prof. Mark Rubin (President) on their 3R's project award. With this 3RCC funding they will develop a platform for GU cancer patient-derived organoids.

Discovery of new genes that influence the success of cancer treatment

One of the great mysteries of cancer research is why certain patients respond better to radiation therapy than others. Researchers at the University of Bern and BCPM have now discovered which genes play an important role in this. This results in new findings for cancer treatment.

Next-Generation Sequencing to provide Precision Medicine for Rare Metabolic Disorders

The group of Amit V. Pandey (DBMR) and Christa E. Flück (DBMR and BCPM member), in collaboration with Laura Audí (Hospital Vall d'Hebron, Autonomous University of Barcelona, Spain), has studied the genetic basis of aromatase deficiency, a rare metabolic disorder that prevents the production of estrogens in humans, according to new research in JCEM (Journal of Clinical Endocrinology and Metabolism).
Image of steroid producing cells grown in the laboratory © Emanuele Pignatti / University of Bern / Inselspital, University Hospital Bern

SRF Digital: Big Data in der Medizin (german podcast)

Prof. Mark Rubin, President of the BCPM, is interviewed about Big Data in Medicine, and in this context, he talks about the Swiss Personalized Health Network (SPHN) (starting 18'10'').

Professor Tosso Leeb, winner of the International Canine Health Award 2020

Prof. Tosso Leeb, Director of the Institute of Genetics of the Vetsuisse Faculty, University of Bern and management board member of the BCPM, has won the International Canine Health Award 2020, one of the largest and most distinguished veterinary awards in the world.

Professor Leeb’s research is focused on the analysis of inherited traits and diseases in domestic animals.

BCPM Project Call on
Covid-19 and SARS-CoV-2

The BCPM a has issued a call for applications for projects on
COVID-19 and SARS-CoV-2. This research call is meant to supplement bigger research programs such as the ones financed by the SNF, and is open to researchers from the Inselspital and University of Bern.

Submission deadline:
Monday, May 18th, 2020,
12:00 (noon) CET.

NEW: Annual Report 2019, Insel Gruppe (in German)

Cloëtta Prize 2020 awarded to Prof. Nadia Mercader

Prof. Nadia Mercader from the Institute of Anatomy of the University of Bern, member of the BCPM and Chair of its Scientific Review Board, has been awarded the 2020 Cloëtta Prize for her outstanding research on heart regeneration.

The Professor Dr Max Cloëtta Foundation aims at supporting and promoting medical research as well as related disciplines of natural sciences in Switzerland.

ERC Advanced Grant awarded to Prof. Dr. Sven Rottenberg, Institute of Animal Pathology at the University of Bern and member of the BCPM

Prof. Dr. Sven Rottenberg has been awarded a prestigious ERC Advanced Grant. His research project TETHER will receive 2,5 mio. EURO in funding for a duration of 5 years, and will focus on the molecular mechanisms of radiotherapy-resistant cancers.

NEW: Annual Report 2019, Medical Faculty, University of Bern

"EVENT POSTPONED": 10x Genomics User Day: "From Single Cell to Spatial Transcriptomics", March 17th 2020, 13:30-17:00, Hörsaal Paraklinik, Länggassstrasse 122, 3012 Bern

This event will feature presentations from 10 x Genomics specialists as well as from Bern and Fribourg researchers. It will be an informative afternoon for any researcher who wants to use or currently uses single-cell sequencing technologies in their research.

Please see the attached flyer for further details and for the registration link. Places are limited!

«Es gibt keine perfekte Medizin – nur eine effizientere»

BCPM director Mark Rubin is interviewed (in german) on precision medicine and how it can improve the treatment of patients as well as promote disease prevention.

Gut bacteria help control healthy muscle contraction in the colon

Micro-organisms in the gut support healthy digestion by helping nerve cells within the intestine to regulate the contraction and relaxation of the muscle wall of the colon, according to new research from the Francis Crick Institute and Bern University.

Collegium Generale Lecture Series: Dr. Rémy Bruggmann "Bioinformatik und Sequenziertechnologien" (Podcast in german)

Dr. Rémy Bruggmann, Head of the Interfaculty Bioinformatics Unit, University of Bern and BCPM management board member, speaks about Bioinformatics and Sequencing Technologies.

Prof. Jean-Pierre Hubaux, EPFL: "Data Protection for Personalized Health"

Check out the presentation slides from the BCPM seminar held on October 15, 2019.

“Bern is ideally suited for precision medicine”

Article published in Uniaktuell 20.09.2019

Making precision medicine a reality in Switzerland

Prof. Daniel Candinas, Vice-Rector for Research at the University of Bern and Managing Director of the Department of Visceral Surgery and Medicine, Inselspital, University Hospital of Bern speaks of his role in the Bern Center for Precision Medicine (BCPM)

BCPM Director Mark Rubin, one of the winners of ICPerMed "Best Practice in Personalised Medicine" Recognition 2019

Precision medicine is an approach that takes into account the influence of individuals' genes, environment, and lifestyle exposures to tailor interventions. Here, we describe the development of a robust precision cancer care platform that integrates whole-exome sequencing with a living biobank that enables high-throughput drug screens on patient-derived tumor organoids.